08/05/2026
A 2025 preclinical study investigated whether intranasally delivered human Dezawa MuseCellsยฎ could improve recovery after ischemic stroke in a mouse model.
๐ง๐ต๐ฒ ๐ฆ๐๐๐ฑ๐
Researchers induced ischemic stroke in mice and, seven days later, administered purified human MUSE cells through the nasal cavity. Outcomes were compared with mice receiving mesenchymal signaling cells (MSCs) or a vehicle control. Motor function was assessed for 84 days, and researchers examined whether the transplanted cells reached and integrated into the injured brain tissue.
๐๐ฒ๐ ๐๐ถ๐ป๐ฑ๐ถ๐ป๐ด๐
๐น Mice treated with intranasal MUSE cells showed sustained improvements in motor function. Low-dose MSCs showed no significant benefit, while high-dose MSCs produced only temporary improvement.
๐น MUSE cells migrated to the stroke injury and engrafted at much higher levels than MSCs.
๐น Many transplanted MUSE cells expressed neuronal and oligodendrocyte markers, suggesting integration into damaged tissue.
๐น The findings support intranasal delivery as a minimally invasive route for administering MUSE cells after ischemic stroke.
These results suggest intranasal MUSE cell therapy may promote structural repair and long-term functional recovery following ischemic stroke in this animal model.
๐๐ถ๐บ๐ถ๐๐ฎ๐๐ถ๐ผ๐ป๐
๐น This was a preclinical mouse study, not a human clinical trial.
๐น Only one behavioral test was used, and cognitive outcomes were not evaluated.
๐น Additional research is needed to determine optimal dosing, repeat treatment strategies, and whether these findings translate to patients.
๐ง๐ต๐ฒ ๐ง๐ฎ๐ธ๐ฒ๐ฎ๐๐ฎ๐
Purified human Dezawa MuseCellsยฎ delivered intranasally reached the injured brain, integrated into damaged tissue, and improved long-term motor recovery in a mouse model of ischemic stroke. While encouraging, human clinical studies are needed to determine whether this approach is safe and effective in people.
PMID: 40346279
๐๐ฏ๐ง๐ฐ๐ณ๐ฎ๐ข๐ต๐ช๐ฐ๐ฏ๐ข๐ญ ๐ฐ๐ฏ๐ญ๐บ. ๐๐ฐ๐ต ๐ฎ๐ฆ๐ฅ๐ช๐ค๐ข๐ญ ๐ข๐ฅ๐ท๐ช๐ค๐ฆ.
